Clinical trials: sponsored by Henry Ford Health System
Diabetes Mellitus
Feasibility Study of Finesse for Bolus Prandial Insulin Dosing Compared to Multiple Daily Injections
The purpose of this study is to evaluate that Finesse, for prandial insulin bolusing when used in conjunction with basal insulin, achieves equivalent glycemic control when compared to multiple daily injections and to evaluate its…
- Trial name
- NCT01073566
- Testing
- Finesse, Pen/Syringe (Usual injection device)
- Where
- 5 sites in United States
- Volunteers
- 38 people
- Sponsor
- Calibra Medical, Inc.
Cardiovascular Diseases
CardioSeq: Impact of WGS in Individuals With CVD
This is a prospective, single-center, open-label study to investigate the diagnostic efficacy of the TruGenome CVD test and its impact on clinical management compared to usual care in individuals with cardiovascular disease.
- Trial name
- NCT05656183
- Testing
- TruGenome Cardiovascular Disease test
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- Illumina, Inc.
Venous Stasis Ulcers
The Effects of Pulsed Elelectro-Magnetic Fields ("PEMF") in the Treatment of Venous Stasis Leg Ulcers
The purpose of this study is to determine the clinical effectiveness of a low-power PEMF device, a medium-power PEMF device and a high-power PEMF device as compared to a sham device to treat leg ulcers resulting from venous…
- Trial name
- VSLU (NCT03416049)
- Testing
- PEMF therapy with a high-power PEMF device, PEMF therapy with a medium PEMF power device, PEMF therapy with a low-power PEMF device
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- PEMF Systems, Inc.
Carcinoma, Non-Small-Cell Lung
BIO 300 Non-Small Cell Lung Cancer Study
The purpose of this study is to determine the safety and effectiveness of BIO 300 Oral Suspension when used in combination with standard dose radiation therapy and chemotherapy in patients with non-small cell lung cancer.
- Trial name
- NSCLC (NCT02567799)
- Testing
- BIO 300 Oral Suspension, Paclitaxel, Carboplatin
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Humanetics Corporation
Congenital Heart Disease With Fontan Circulation
An Upcoming Clinical Study to Measure the Safety and Impact of a Drug Called Macitentan in Teenage and Adult Fontan Patients.
The aim of this open-label (OL) trial is to study the long-term use of macitentan for up to 2 years in Fontan-palliated adult and adolescent patients beyond the 52 weeks of treatment in the parent RUBATO double-blind (DB) study…
- Trial name
- RUBATO OL (NCT03775421)
- Testing
- macitentan 10 mg
- Where
- 19 sites in United States, Australia and 9 more
- Volunteers
- 112 people
- Sponsor
- Actelion
Chronic Liver Disease, Hepatocellular Carcinoma (HCC)
Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRI
The Exalenz clinical investigation is a multicenter, non-randomized, study of the ¹³C-Octanoate Breath Test (OBT). The present study is a feasibility trial, which aims to evaluate the capability of the OBT measurement to…
- Trial name
- OBT for HCC (NCT01433016)
- Testing
- 13C Sodium Octanoate
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Meridian Bioscience, Inc.
Pressure Ulcer
Comparative Prevention-effectiveness Trial of DabirAIR Overlay System
Henry Ford Health System will evaluate the DabirAIR overlay system (DOS) for its effectiveness in preventing hospital acquired pressure ulcer (HAPU) in the peri-operative setting.
- Trial name
- NCT02565797
- Testing
- DabirAIR alternating pressure overlay
- Where
- United States
- Volunteers
- 392 people
- Sponsor
- Dabir Surfaces Inc
Non Small Cell Lung Cancer
Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC
Subjects will be eligible for this study if they are about to start on a drug called nivolumab for lung cancer. Some patients' cancers respond to nivolumab but a majority of patients do not.
- Trial name
- NO3DEXPL (NCT03371992)
- Testing
- Nivolumab, 3D-EX, Evaluation of Response by RECIST
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Nilogen Oncosystems
Migraine Disorders, Headache Disorders
Predicting Migraine Attacks Based on Environmental and Behavioral Changes as Detected From the Smartphone
This study is conducted at the Henry Ford Health System with Lifegraph's behavioral monitoring technology, to examine the relation between migraine attacks and behavioral and environmental changes as detected from the smartphone…
- Conditions
- Migraine Disorders, Headache Disorders, Headache Disorders, Primary, Brain Diseases
- Trial name
- Migraine (NCT03762902)
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Lifegraph Ltd.
Solitary Pulmonary Nodule, Multiple Pulmonary Nodules
A Multi-Center Trial of the ProLung Test™
The primary Study hypothesis is that the ProLung Test will demonstrate safety and efficacy in the risk stratification of patients with pulmonary lesions identified by CT that are suspicious for lung cancer.
- Trial name
- NCT01566682
- Where
- 15 sites in United States
- Volunteers
- 420 people
- Sponsor
- Fresh Medical Laboratories
Methicillin-Resistant Staphylococcus Aureus (MRSA), Hospital-Acquired Pneumonia
Evaluation of Patients With Methicillin-Resistant Staphylococcus Aureus Hospital-Acquired Pneumonia Treated With Linezolid or Vancomycin
The objective of this study is to review the local management of patients with methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia treated with vancomycin or linezolid with the goal to define if any difference…
- Trial name
- NCT01561469
- Testing
- Linezolid, Vancomycin
- Volunteers
- 188 people
- Sponsor
- Pfizer
Acute Coronary Syndrome
Veliflapon (DG-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina
The purpose of this study is to determine if veliflapon (DG-031)can prevent a heart attack or stroke in African American patients with a history of unstable angina or myocardial infarction.
- Trial name
- NCT00353067
- Testing
- veliflapon (DG-031)
- Where
- 11 sites in United States
- Volunteers
- 3,450 people
- Sponsor
- deCODE genetics